Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in the EU / 2025-522809-38-00
Authorised, recruiting Phase III

Continuous antibiotic infusion in children

2025-522809-38-00 · tracked via the Priya Life Science EU tracker
Sponsor
Pirkanmaan hyvinvointialue
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Bacterial Infections and Mycoses
Decision date
16/02/2026
Enrollment target
150
Sites
Finland

Condition studied

Infection disease

Investigational medicinal product(s)

Cloxacillin Navamedic 2 g injektio-/infuusiokuiva-aine liuosta vartenBenzylpenicillin Fresenius Kabi 1,2 g (2 milj. IU) injektio-/infuusiokuiva-aine liuosta vartenPiperacillin/Tazobactam Kalceks 2 g/0,25 g infuusiokuiva-aineliuosta vartenVancosan 500 mgInfuusiokuiva-aine

Eligibility

Age group
0-17 years
Sex
Female, Male

Primary endpoint

Duration of hospital stay / fever / antibiotic treatment, Readmission to hospital, Possible relapse (defined separately for each patient case)

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-522809-38-00 on CTIS ↗ ← All trials in the EU